Firm targets scientific trials of remedies designed to counter the harm incurred by our genome as we age.
Longevity biotech Matter Bio revealed in the present day that it has closed a $7 million seed funding spherical to advance its work focusing on genome integrity to increase human lifespan. The corporate’s mission is to gradual and reverse key drivers of ageing by counteracting the harm incurred by our genome as we age.
Matter’s strategy is predicated on the concept that ageing is outlined by harm that’s integrated into our DNA within the type of mutations, structural variations, epigenetic drift and different sorts of data loss. The corporate goals to counter this harm by creating therapeutics that tackle key levels within the “genomic data loss continuum.”
Detect, reverse, take away
Leveraging a three-pronged technique, Matter’s strategy first detects and identifies lack of genomic data, then corrects these mutations and reintroduces authentic genetic data, earlier than lastly eliminating cells too broken to restore, similar to cancerous, clonal and senescent cells.
“We’re excited to see the rising consensus on the core function DNA harm and mutations play in ageing and age-driven pathologies,” Matter Bio CEO Chris Bradley informed us. “As one of many few firms tackling this large and underserved want, we sit up for additional de-risking our cutting-edge science and crafting transformative medicines for sufferers.”
The corporate is supported by a distinguished staff of scientists, together with co-founders George Church, a pacesetter in genome sequencing and gene modifying, Jan Vijg, an skilled in genome instability and somatic mutations, and Claudia Gravekamp, identified for her work in attenuated bacterial therapeutics.
“Genomic integrity is a cornerstone of longevity and healthspan extension,” mentioned Church, Professor of Genetics at Harvard Medical Faculty. “Matter Bio is pioneering an important strategy within the battle towards ageing by specializing in the preservation of our genetic blueprint. I’m excited to see the influence of their work on enhancing human well being.”
Concentrating on scientific trials
The seed capital raised will facilitate Matter’s ongoing analysis into the data idea of ageing at a genomic stage. The corporate additionally says the funds will assist file an Investigational New Drug (IND) utility and provoke a Part 1/2a scientific trial focusing on stable cancers.
“With our staff of rockstar gene modifying and sequencing consultants, we’re uniquely positioned to deal with the lack of genome stability as a driver for ageing,” Matter Bio co-founder, Dr Sam Sharifi informed us. “Our modern strategy leverages bleeding-edge gene modifying and sequencing applied sciences to develop therapies that restore genome integrity, probably remodeling the therapy of age-related illness.”
The seed spherical was led by Lifespan Imaginative and prescient Ventures with contributions from quadraScope Ventures and extra assist from grants by NIH, NCI and NIEHS.
“Our funding in Matter Bio furthers our mission of supporting the cutting-edge interventions that promote longevity and fight ageing,” mentioned Andrew Worden, Founding Associate of LifeSpan Imaginative and prescient Ventures. “Matter Bio’s sturdy staff, cutting-edge genomic preservation applied sciences, and early-stage partnerships give the corporate glorious prospects to succeed with its imaginative and prescient.”
